Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma
- PMID: 20501857
- DOI: 10.1158/0008-5472.CAN-10-0120
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma
Abstract
Sporadic clear cell renal cell carcinoma (cRCC) is genetically characterized by the recurrent loss of the short arm of chromosome 3, with a hotspot for copy number loss in the 3p21 region. We applied a method called "gene identification by nonsense-mediated mRNA decay inhibition" to a panel of 10 cRCC cell lines with 3p21 copy number loss to identify biallelic inactivated genes located at 3p21. This revealed inactivation of the histone methyltransferase gene SETD2, located on 3p21.31, as a common event in cRCC cells. SETD2 is nonredundantly responsible for trimethylation of the histone mark H3K36. Consistent with this function, we observed loss or a decrease of H3K36me3 in 7 out of the 10 cRCC cell lines. Identification of missense mutations in 2 out of 10 primary cRCC tumor samples added support to the involvement of loss of SETD2 function in the development of cRCC tumors.
Copyright 2010 AACR.
Similar articles
-
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.Cancer Res. 2001 Oct 1;61(19):7277-81. Cancer Res. 2001. PMID: 11585766
-
Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).Urol Oncol. 2013 Oct;31(7):1333-42. doi: 10.1016/j.urolonc.2011.08.012. Epub 2011 Oct 1. Urol Oncol. 2013. PMID: 21962529
-
Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.Neoplasia. 2016 Jun;18(6):339-46. doi: 10.1016/j.neo.2016.04.005. Epub 2016 May 26. Neoplasia. 2016. PMID: 27292023 Free PMC article.
-
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
-
SETD2: an epigenetic modifier with tumor suppressor functionality.Oncotarget. 2016 Aug 2;7(31):50719-50734. doi: 10.18632/oncotarget.9368. Oncotarget. 2016. PMID: 27191891 Free PMC article. Review.
Cited by
-
Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.J Biol Chem. 2016 Sep 30;291(40):21283-21295. doi: 10.1074/jbc.M116.739375. Epub 2016 Aug 15. J Biol Chem. 2016. PMID: 27528607 Free PMC article.
-
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology.Chin J Cancer Res. 2016 Feb;28(1):80-91. doi: 10.3978/j.issn.1000-9604.2016.02.09. Chin J Cancer Res. 2016. PMID: 27041930 Free PMC article. Review.
-
Renal cell carcinoma deep sequencing: recent developments.Curr Oncol Rep. 2012 Jun;14(3):240-8. doi: 10.1007/s11912-012-0230-3. Curr Oncol Rep. 2012. PMID: 22535504 Review.
-
A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.Genetics. 2024 Apr 3;226(4):iyae015. doi: 10.1093/genetics/iyae015. Genetics. 2024. PMID: 38290049 Free PMC article.
-
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.Mol Genet Genomic Med. 2020 Feb;8(2):e1079. doi: 10.1002/mgg3.1079. Epub 2019 Dec 23. Mol Genet Genomic Med. 2020. PMID: 31867841 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases